filmov
tv
Triplet Regimens in BRAF-Mutant Metastatic CRC
Показать описание
The rationale for using triplet regimens in patients with BRAF-mutant metastatic colorectal cancer based on findings from the SWOG S1406 and BEACON CRC studies.
Triplet Regimens in BRAF-Mutant Metastatic CRC
Triplet Regimen Improves Responses in BRAF V600E+ Metastatic CRC
BEACON Trial: Triplet Therapy in BRAF V600E–Mutated mCRC
Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma
Triplet Therapy for Certain Patients with Metastatic CRC Shows Promise, But More Research is Needed
Targeting BRAF in Metastatic CRC
Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC
Case 1: BRAF-Mutated Metastatic Colorectal Cancer
Real-World Management of Patients with BRAF-V600E mCRC
Safety Lead-In Data for BEACON CRC Trial With Triplet Biologic Regimen in mCRC
First-Line Triplet in BRAF+ mCRC
Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer
Initial Management of Metastatic CRC in 2019
BRAF-Mutated mCRC: From Diagnosis to Treatment
Metastatic Melanoma - Doublet vs Triplet therapy
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic ......
Colorectal Cancer Debate: First Line BRAF V600E - Targeted Triplet
What is the optimal therapy for BRAF mutant metastatic colorectal cancer?
Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC
Sequencing Strategies in BRAF-Mutated mCRC
Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer
Next Steps After Phase III BEACON CRC Trial in mCRC
Encorafenib & Binimetinib + Cetuximab for Untreated BRAF V600E-Mutant Metastatic Colorectal Canc...
